Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Alnylam Pharmaceuticals Ownership Summary


Alnylam Pharmaceuticals is owned by 21.83% institutional investors, 0.18% insiders, and 77.99% retail investors. Fmr is the largest institutional shareholder, holding 11.03% of ALNY shares. American Funds Growth Fund of Amer A is the top mutual fund, with 6.01% of its assets in Alnylam Pharmaceuticals shares.

ALNY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAlnylam Pharmaceuticals21.83%0.18%77.99%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr14.58M11.03%$4.82B
Vanguard group13.55M10.31%$5.39B
Capital world investors10.80M8.17%$3.57B
Blackrock funding, inc. /de10.44M7.90%$3.46B
Blackrock9.55M7.57%$2.32B
Capital research global investors9.47M7.16%$3.13B
Jpmorgan chase6.32M4.78%$2.00B
T. rowe price investment management5.19M3.93%$1.72B
State street3.32M2.51%$1.10B
Geode capital management2.66M2.01%$884.57M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Prosight management, lp76.00K4.12%$25.15M
Rosenblum silverman sutton s f inc /ca32.93K2.85%$10.89M
Palo alto investors lp32.32K2.73%$14.74M
Quantessence capital15.87K2.29%$7.24M
Susquehanna advisors group286.10K2.00%$130.46M
Casdin capital75.00K1.88%$24.82M
Orbis allan gray1.33M1.86%$441.65M
Bellevue group234.54K1.85%$77.60M
Soleus capital management131.65K1.76%$43.56M
Polymer capital management (hk)57.78K1.65%$19.12M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management5.19M1.18%3.44M
Capital research global investors9.47M0.49%2.69M
Norges bank2.25M0.10%2.25M
Jpmorgan chase6.32M0.13%1.60M
Two sigma investments, lp1.99M0.53%1.38M

Top Sellers

HolderShares% AssetsChange
Capital world investors10.80M0.49%-5.50M
Regeneron pharmaceuticals---1.39M
Fmr14.58M0.25%-1.32M
Arrowstreet capital, limited partnership---1.13M
Invesco1.29M0.07%-874.11K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.25M0.10%2.25M$895.82M
Vanguard fiduciary trust840.89K0.07%840.89K$278.22M
Susquehanna advisors group286.10K2.00%286.10K$130.46M
Vanguard asset management219.24K0.06%219.24K$72.54M
Bank of america corp /de/83.50K0.00%83.50K$20.29M

Sold Out

HolderChange
Rise advisors-1.00
Salem investment counselors-1.00
Bear mountain capital-1.00
Financial gravity asset management-1.00
Kohmann bosshard financial services-1.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026458-48.42%28,867,328-77.75%210.22%228-49.78%136-53.42%
Dec 31, 2025684-20.56%91,965,556-31.27%690.66%343-32.61%2325.45%
Sep 30, 202582219.83%128,435,377-3.80%990.93%48136.26%215-3.15%
Jun 30, 20256852.09%133,478,5513.70%1021.04%3541.14%22010.00%
Mar 31, 202528-95.52%1,770,848-98.63%10.01%11-96.63%10-94.71%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
American Funds Growth Fund of Amer A8.02M6.01%-1.79M
Capital Group Growth Fnd of Amer Comp8.02M6.01%-1.79M
Vanguard Total Stock Mkt Idx Inv4.23M3.17%10.13K
Vanguard US Total Market Shares ETF4.07M3.15%54.28K
VA CollegeAmerica Amcap 529A3.73M2.89%658.62K
Capital Group AMCAP Composite3.74M2.81%1.53M
American Funds AMCAP A3.74M2.81%1.53M
Vanguard Mid Cap Index Institutional2.87M2.15%6.42K
Invesco QQQ Trust2.84M2.13%20.86K
Capital Group New Perspective Comp2.39M1.80%-370.32K

Recent Insider Transactions


DateNameRoleActivityValue
Apr 02, 2026McLaughlin Melissa Chief Human Resources OfficerSell$66.56K
Apr 02, 2026McLaughlin Melissa Chief Human Resources OfficerSell$27.49K
Apr 02, 2026McLaughlin Melissa Chief Human Resources OfficerSell$83.90K
Apr 02, 2026McLaughlin Melissa Chief Human Resources OfficerSell$113.96K
Apr 02, 2026McLaughlin Melissa Chief Human Resources OfficerSell$47.13K

Insider Transactions Trends


DateBuySell
2026 Q2-14
2026 Q1-228
2025 Q4-96
2025 Q3-80
2025 Q2-17

ALNY Ownership FAQ


Who Owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals shareholders are primarily institutional investors at 21.83%, followed by 0.18% insiders and 77.99% retail investors. The average institutional ownership in Alnylam Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Alnylam Pharmaceuticals falls below.

Who owns the most shares of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s largest shareholders are Fmr (14.58M shares, 11.03%), Vanguard group (13.55M shares, 10.31%), and Capital world investors (10.8M shares, 8.17%). Together, they hold 29.51% of Alnylam Pharmaceuticals’s total shares outstanding.

Does Blackrock own Alnylam Pharmaceuticals?

Yes, BlackRock owns 7.57% of Alnylam Pharmaceuticals, totaling 9.55M shares as of Jun 2024. This represents 0.05% of BlackRock's total assets, with a market value of 2.32B$. In the last quarter, BlackRock increased its holdings by 522.66K shares, a 5.79% change.

Who is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Prosight management, lp is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.12% of its assets in 76K Alnylam Pharmaceuticals shares, valued at 25.15M$.

Who is the top mutual fund holder of Alnylam Pharmaceuticals shares?

American Funds Growth Fund of Amer A is the top mutual fund holder of Alnylam Pharmaceuticals shares, with 6.01% of its total shares outstanding invested in 8.02M Alnylam Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools